Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Rigetti Computing Shares Under Pressure Ahead of Earnings Report

Felix Baarz by Felix Baarz
November 7, 2025
in AI & Quantum Computing, Analysis, Earnings, Trading & Momentum
0
Rigetti Stock
0
SHARES
48
VIEWS
Share on FacebookShare on Twitter

The quantum computing specialist Rigetti Computing finds its equity under significant selling pressure as the company approaches its quarterly earnings announcement. Market unease has been triggered by a recent analyst downgrade, with trading patterns indicating substantial investor anxiety. Simultaneously, unusual activity in the options market suggests traders are positioning for potential volatility, raising questions about whether Rigetti stands at a critical juncture.

Quarterly Results Loom as Pivotal Moment

All eyes are on November 10, when Rigetti is scheduled to release its third-quarter 2025 financial results after US markets close. Analyst expectations remain modest, with revenue projections hovering around $2.39 million. This conservative outlook itself presents a risk—should the company fail to meet even these tempered expectations or provide weak forward guidance, further share price deterioration appears likely.

Conversely, any positive surprises regarding the commercialization progress of its quantum processors or announcements of new strategic partnerships could potentially reverse the current negative sentiment. The situation remains highly fluid, with volatility metrics reaching 140 percent, indicating that sharp price movements in either direction remain possible. Management will host a conference call on November 11 to contextualize the results and provide future guidance, offering investors a crucial assessment of whether Rigetti can counter skepticism about its path to profitability.

Analyst Downgrade Triggers Sell-Off

Market confidence received a sharp blow on November 6 when investment bank B. Riley downgraded Rigetti to a “Neutral” rating. The immediate market reaction was severe, with shares plunging 10.1 percent following the announcement. While appearing as a straightforward rating adjustment, the downgrade has broader implications, triggering capital outflows and forcing investors to reassess growth projections for the inherently volatile stock.

Should investors sell immediately? Or is it worth buying Rigetti?

This revised analyst stance primarily signals growing doubts about the company’s near-term performance capabilities. While quantum computing maintains its long-term promise as a transformative technology, market experts appear increasingly cautious about Rigetti’s prospects over the coming months. The fundamental challenge remains that the company must demonstrate both technological progress and financial stability—with the latter currently representing the primary concern.

Options Trading Reveals Defensive Positioning

Activity in the options market further underscores the prevailing uncertainty. Trading volume reached approximately 217,000 contracts on November 6—a notably elevated level. More significantly, the distribution of activity revealed a defensive bias: 58.2 percent of transactions involved put options (positions benefiting from price declines), compared to just 41.8 percent for call options (positions benefiting from price increases).

Key options market statistics:

  • November 6 trading volume: 216,960 contracts
  • Put options represented: 58.19%
  • Call options represented: 41.81%
  • Total open interest: approximately 1.17 million contracts

These metrics suggest investors are either implementing significant protection against additional share price declines or actively speculating on further downside. The substantial open interest additionally indicates that numerous institutional participants have already established positions, leaving market observers to question what catalyst these traders anticipate.

Ad

Rigetti Stock: Buy or Sell?! New Rigetti Analysis from February 7 delivers the answer:

The latest Rigetti figures speak for themselves: Urgent action needed for Rigetti investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Rigetti: Buy or sell? Read more here...

Tags: Rigetti
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Apple Stock

Apple Bets Big on Google AI in Strategic Pivot

Keurig Dr Pepper Stock

Keurig Dr Pepper's Strategic Overhaul: A High-Stakes Transformation

Intellia Therapeutics Stock

Clinical Trial Setback Sends Intellia Shares Plummeting

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com